Prospective randomized study investigating safety and efficacy of Everolimus of preemptive prophylaxis of cytomegalovirus infection (CMV) in kidney transplant patients

Trial Profile

Prospective randomized study investigating safety and efficacy of Everolimus of preemptive prophylaxis of cytomegalovirus infection (CMV) in kidney transplant patients

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate mofetil
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Nov 2015 New trial record
    • 16 Sep 2015 Results presented at the 17th Congress of the European Society for Organ Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top